Randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high risk multiple myeloma (SWOG-1211).
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Saad Zafar Usmani, Antje Hoering, Sikander Ailawadhi, Rachael Sexton, Brea Lipe, Jason Neil Valent, Michael Alan Rosenzweig, Jeffrey A. Zonder, Madhav V. Dhodapkar, Natalie Scott Callander, Todd M. Zimmerman, Peter M. Voorhees, Brian G. Durie, S. Vincent Rajkumar, Paul G. Richardson, Robert Z. Orlowski
Institutions: Memorial Sloan Kettering Cancer Center, Cancer Research And Biostatistics, Mayo Clinic in Florida, University of Rochester, Cleveland Clinic, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Yale University, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, University of Chicago, Levine Cancer Institute, Cedars-Sinai Medical Center, Mayo Clinic, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: National Institutes of Health
OpenAlex ID: W4286297641